A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

This study is testing a combination of two drugs — BL-B01D1 (an antibody-drug conjugate) and almonertinib (a targeted therapy) — given before surgery in patients with non-small cell lung cancer (NSCLC) that has a specific genetic change called an EGFR mutation. The goal is to shrink the tumor before surgical removal and improve long-term outcomes. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with stage II to IIIB non-small cell lung cancer with an EGFR mutation (a specific gene change that makes your cancer sensitive to targeted drugs) - Your cancer is potentially removable by surgery after pre-treatment (neoadjuvant therapy) - Your heart and lung function are adequate - Your blood counts and organ function meet required thresholds **You may NOT be eligible if...** - Your cancer does not have the EGFR mutation - Your cancer has spread beyond the lung to distant sites - You have significant heart problems (ejection fraction below 50%) - You have previously received surgery-targeting or EGFR-targeted treatment for this cancer Talk to your doctor to see if this trial is right for you.